Clinical Trial

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Name: Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer — clinical trial record (NCT07265739)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-11-23; most recent amendment 2026-05-05.

Trial Details

NCT Number	NCT07265739
Lead Sponsor	Massachusetts General Hospital Collaborators: American Cancer Society, Inc.
Conditions	Platinum Resistant Ovarian Cancer
Enrollment	27 participants
Start Date	2026-08
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-06